Treats multiple myeloma. Sold as Ninlaro. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Ixazomib Citrate (sold as Ninlaro), first approved Nov 20, 2015, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Ninlaro | Part D | $247M | -9% | 2,665 |
| A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizeHIV (Human Immunodeficiency Virus) · National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | Oct 19, 2026 |
| SIL as Maintenance Therapy in Multiple MyelomaMultiple Myeloma · Navy General Hospital, Beijing | Phase 2 | Not yet recruiting | Dec 20, 2024 |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaMultiple Myeloma · Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 4 | Recruiting | Feb 10, 2023 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisAL Amyloidosis · Columbia University | Phase 1 / Phase 2 | Active, not recruiting | Jul 11, 2022 |
| A Study of NINLARO® in Chinese Adults With Multiple MyelomaMultiple Myeloma · Takeda | — | Active, not recruiting | Aug 19, 2021 |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Multiple Myeloma at First Relapse · Nantes University Hospital | Phase 2 | Active, not recruiting | Aug 10, 2021 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisRecurrent AL Amyloidosis, Refractory AL Amyloidosis · National Cancer Institute (NCI) | Phase 1 | Active, not recruiting | Apr 19, 2021 |
| Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and BortezomibMultiple Myeloma in Relapse, Refractory Multiple Myeloma · Tel-Aviv Sourasky Medical Center | Phase 2 | Active, not recruiting | Mar 10, 2021 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 20, 2015 | NinlaroNDA 208462 · New molecular entity | Takeda Pharms USA | 9 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
